fbpx

About

PAUL IAN CROSS PhD is a scientist from London, UK. Paul works in clinical research (developing new medicines) and he’s also a science communicator (presenting science to non-scientists).

Paul writes STEM-inspired fiction, and has a passion for introducing children to STEM subjects; particularly reluctant readers.

By introducing science creatively, he aims to spark their interest, allowing them to gain confidence with their reading.

You can read more about his award winning fiction here.

Dr Paul’s CV

National Institute for Health Research

GCP Subject Matter Expert and Learning Advisor (May 2019 – Present)

Guy’s and St Thomas’ NHS Foundation Trust, Biomedical Research Centre (BRC)

Research and Development (R&D) Quality Assurance Manager (Dec 2010 – Aug 2017)

ICNARC Clinical Trials Unit (Intensive Care National Audit and Research Centre)

Trial Manager (Optimise) (Jun 2010 – Nov 2010)

Research and Development Office for Great Ormond Street Hospital for Children NHS Trust & the UCL Institute of Child Health (ICH)

Clinical Trials Manager (March 2008 – May 2010)

St George’s, University of London

Clinical Studies Coordinator (April 2006 – May 2008)

Barts & The London NHS Trust

Clinical Research Scientist (March 2005 – April 2006)

Hammersmith Medicines Research

Clinical Research Technician and Quality Coordinator (March 2004 – March 2005)

Academic Experience

Cardiff University

Doctor of Philosophy (PhD) (Mar 2019)

MSc in Clinical Research with Distinction (Jun 2012)

University of Central Lancashire

University Certificate in Astronomy (Oct 2011)

        

Nottingham Trent University

BSc (Hons) Applied Biology 2:1 (Sandwich Course – June 2003)

        

Conference Presentations

Cross, P. I. and Gibson, J. (2017), Demystifying Computer Systems Validation, Parallel Session at the UK Clinical Research Facility Conference, Glasgow

Cross, P. I. and Ward, A. (2016), Quality assurance: everybody’s business, Parallel Session at the UK Clinical Research Facility Conference, Manchester

Cross, P.I. (2015), Risk assessment at Investigator Sites / Quality: the responsibility of all, Opening plenary conference presentations, Global Health Clinical Trials Network /University of Cape Town, Groot Shuur Hospital, Cape Town, South Africa

Cross, P. I. and Sexton, C. (2015), Document Management Systems, Parallel Session at the UK Clinical Research Facility Conference, Royal College of Physicians, London, UK

Cross , P. I. and Sewell, R. (2015), Developing a model for the benefit-risk assessment of medicines, incorporating patient views as key criteria in decision making, Closing Plenary conference presentation at the UK Clinical Research Facility Conference, Royal College of Physicians, London, UK

Cross, P. I. (2010), Sponsor responsibilities, NEMO-1 Clinical Trial Investigator Meeting, Cork, Ireland

Conference Posters

Cross, P. I. and Sewell, R. (2016), Developing and validating a semi-quantitative model for the benefit-risk assessment of medicines, incorporating patient views as key criteria in decision making, RQA European Conference Poster, Nice, France

Tiemens, L. and Cross, P. I. (2014), Implementation of a standard governance system across an Imaging CRF, UK Clinical Research Facility Conference Poster, Sheffield CRF/ University of Sheffield, UK

Darroch, P., Cross, P. I. and Dobbyn, J. (2013), The Use of Simulation in the Training of Clinical Research Facility Staff in Emergency Scenarios, UK Clinical Research Facility Conference Poster, Birmingham CRF/University of Birmingham, Birmingham, UK

Cross, P. I. and Salek, M. S., (2012), Pharmacovigilance and the Prevention of Adverse Drug Reactions at Guy’s and St Thomas’ NHS Foundation Trust – A Retrospective Observational Study of ADRs to Warfarin, UK Clinical Research Facility Conference Poster, Clinical Research Centre/Trinity College, Dublin, Ireland

Scientific Publications /

Acknowledgments

Acknowledged in: Pressler et al. (2015). Bumetanide for the treatment of seizures in new born babies with hypoxic ischaemic encephalopathy (NEMO): an open label, dose finding, and feasibility phase 1 / 2 trial. Lancet Neurology.